FindTrial
Sign In

Anthracyclines

DRUG3 trials

Sponsors

University Hospital Muenster, UNICANCER, University Medical Center Groningen

Conditions

Cancer, Treatment-RelatedCardiovascular MorbidityMetastatic Breast CancerMyeloid LeukemiaToxicity Due to Chemotherapy

Phase 2

Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents
NCT00111345
University Hospital MuensterMyeloid Leukemia
Start: 2004-03-31End: 2017-03-31Updated: 2012-05-23
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Active, not recruitingNCT02299999
UNICANCERMetastatic Breast Cancer
Start: 2014-04-07End: 2025-12-31Updated: 2025-01-15

Unknown Phase

Investigating Cardiovascular Adverse Events Related to Cancer Treatment
Active, not recruitingNCT03199300
University Medical Center GroningenCancer, Treatment-Related, Cardiovascular Morbidity, Toxicity Due to Chemotherapy
Start: 2017-12-12End: 2027-01-31Updated: 2025-12-11

Related Papers

Prognostic Value of Molecular Genetic Measurable Residual Disease ( <scp>MRD</scp> ) Monitoring in Pediatric Acute Myeloid Leukemia Expressing <i>KMT2A::MLLT10</i>
European Journal Of Haematology2025-08-131 citations
Mapping the rapid growth of multi-omics in tumor immunotherapy: Bibliometric evidence of technology convergence and paradigm shifts
Human Vaccines & Immunotherapeutics2025-04-243 citations
251P Genomic alterations of breast cancer patients with leptomeningeal disease: A retrospective analysis
ESMO Open2024-05-011 citations
Genomics to select treatment for patients with metastatic breast cancer.
2022-09-07119 citations
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
Genome Medicine2021-05-1853 citations
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
2020-01-24221 citations
Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation
Cancer Research2019-07-012 citations
Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation
Clinical Research (Excluding Clinical Trials)2019-07-01
An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.
Journal of Clinical Oncology2018-05-205 citations
Treatment for Metastatic HER2 Breast Cancer Patients With High Loss of Heterozygosity
Oncology Times2017-08-04
Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
2016-11-0115 citations
Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.
2016-01-2718 citations
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
2013-05-23132 citations
Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML.
2007-12-148 citations